Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 24 of 24 entries
View as:

Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04843449 Org: User:
Start: 04/04/21 End: 05/14/21 Due: 05/14/22

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04352361 Org: User:
Start: 04/02/20 End: 04/29/20 Due: 04/29/21

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

Phase: N/A Priority: Normal
NCT ID: NCT05596045 Org: User:
Start: 11/28/22 End: 10/09/23 Due: 10/09/24

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Phase: N/A Priority: Normal
NCT ID: NCT03288636 Org: User:
Start: 08/08/17 End: 10/28/17 Due: 10/28/18

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04547894 Org: User:
Start: 11/09/20 End: 12/07/20 Due: 12/07/21

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT06192264 Org: User:
Start: 01/23/24 End: 05/19/25 Due: 05/19/26

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04965337 Org: User:
Start: 07/11/21 End: 08/01/21 Due: 08/01/22

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT06248008 Org: User:
Start: 04/18/24 End: 03/09/26 Due: 03/09/27

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Phase: N/A Priority: Normal
NCT ID: NCT03020095 Org: User:
Start: 08/31/15 End: 02/28/17 Due: 02/28/18

Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

Phase: N/A Priority: Normal
NCT ID: NCT05107778 Org: User:
Start: 01/10/22 End: 12/14/23 Due: 12/14/24

A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Phase: N/A Priority: Normal
NCT ID: NCT04465890 Org: User:
Start: 07/17/20 End: 08/09/24 Due: 08/09/25

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Phase: N/A Priority: Normal
NCT ID: NCT03430830 Org: User:
Start: 01/15/18 End: 04/09/18 Due: 04/09/19

A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04358523 Org: User:
Start: 03/20/20 End: 12/15/20 Due: 12/15/21

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT03362814 Org: User:
Start: 07/01/17 End: 04/24/19 Due: 04/24/20

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Phase: N/A Priority: Normal
NCT ID: NCT03019991 Org: User:
Start: 10/31/15 End: 11/30/15 Due: 11/30/16

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Phase: N/A Priority: Normal
NCT ID: NCT05118776 Org: User:
Start: 01/21/22 End: 06/30/25 Due: 06/30/26

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Phase: N/A Priority: Normal
NCT ID: NCT03020004 Org: User:
Start: 01/31/16 End: 02/28/17 Due: 02/28/18

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04527250 Org: User:
Start: 09/16/20 End: 12/30/20 Due: 12/30/21

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Phase: N/A Priority: Normal
NCT ID: NCT05330143 Org: User:
Start: 06/28/22 End: 05/15/24 Due: 05/15/25

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT05104125 Org: User:
Start: 01/12/22 End: 04/10/23 Due: 04/10/24

Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05718518 Org: User:
Start: 01/13/23 End: 04/14/23 Due: 04/14/24

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05523141 Org: User:
Start: 10/07/22 End: 12/05/22 Due: 12/05/23

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Phase: N/A Priority: Normal
NCT ID: NCT03020082 Org: User:
Start: 06/30/16 End: 05/31/17 Due: 05/31/18

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

Phase: N/A Priority: Normal
NCT ID: NCT03020134 Org: User:
Start: 07/15/16 End: 08/22/16 Due: 08/22/17